Lipocine reports Q3 2026 results, highlights BLOOM study launch for LPCN 1154
The company started its Phase 3 BLOOM trial in postpartum depression in September 2026 and reported $28.5 million in cash as of November 4, 2026.
SEC filing
4 stories
The company started its Phase 3 BLOOM trial in postpartum depression in September 2026 and reported $28.5 million in cash as of November 4, 2026.
SEC filing
Verity Pharmaceuticals, Lipocine's North American licensing partner, plans to launch the oral testosterone capsule in Canada by the end of 2026.
SEC filing